ClinicalTrials.gg
CompletedNCT07153159Updated Oct 20, 2026

A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Women

A Phase 1 interventional study of Etrasimod in Healthy Participant, sponsored by Pfizer. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Updated Oct 20, 2026Now CompletedNow Active, not recruiting+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

This study aims to figure out how much etrasimod, a medication, ends up in breast milk after taking it for several days. To do this, the researchers will work with at least 8 healthy women who are breastfeeding. These women will take a 2 mg dose of etrasimod every day for 7 days while staying at the testing site. During the study, they won't be allowed to breastfeed their babies to keep the babies safe. Instead, they need to have another plan for feeding their babies during this time. The study will look at how the medication is absorbed and how it moves through the body, checking things like the highest level in the blood and how long it takes to reach that level. The researchers will also see how much of the drug is in the breast milk compared to the blood and whether it's safe for the women to take. After the last dose, the women will stay at the site for at least another 24 hours before going home, and follow-up safety calls will be made about 14 and 28 to 35 days later. The whole process from start to finish will take about 10 weeks

02

Conditions studied

  • Healthy Participant

Keywords

  • Breast feeding women
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy (as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and 12-lead ECGs) lactating women who are actively breastfeeding or expressing breast milk, who are at least 12 weeks post partum and not currently pregnant (must have a negative pregnancy test), and must be 18 to 55 years of age, inclusive, at the time of signing the document (ICD).
  2. (BMI) of 16-35 kg/m2; and a total body weight >45 kg (99 lb).
  3. Participants must be willing to temporarily discontinue breastfeeding their infants for a total of 21 days, ie, from the evening of the day before Day 1 through to 14 days after the last dose (approximately 8 AM the morning of Day 21). Participants must be willing to regularly pump breasts throughout the study and express breast milk according to a schedule designed to maintain lactation until the completion of breast milk collection

Exclusion criteria

Exclusion

  1. Evidence or history of hematological, renal, endocrine, pulmonary (such as moderate or severe chronic pulmonary disorders like asthma or [COPD]), gastrointestinal, cardiovascular, hepatic, neurological/psychiatric, anaphylactic, ophthalmologic disorders (such as macular edema, uveitis, retinopathy), or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. Participants with history or presence of second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sinoatrial block.
  3. Resting HR \<50 bpm at Screening or pre-randomization on Day 1. Measurement can be repeated up to 3 times to confirm the finding. Mean values will be used if repeated.
  4. Recurrent symptomatic bradycardia or recurrent cardiogenic syncope
  5. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  6. Known immunodeficiency disorder, including positive serology for (HIV), or a first degree relative with a hereditary immunodeficiency, and history of organ transplant (except corneal transplant).
  7. History or evidence of or viruses. Hepatitis B vaccination is allowed.89.
  8. Participants with any of the acute or chronic infections or infection history
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    healthy breast feeding volunteers

    Drug: Etrasimod

Interventions

  • Oral 2 milligrams tablet, once a day for 7 days

06

What researchers measure

Primary outcomes

  1. Area under the etrasimod concentration-time curve in breast milk

    Time frame: Baseline (Day -1), Day 1, Day 7 and Day 8.

  2. Maximum observed concentration of etrasimod in breast milk

    Time frame: Baseline (Day -1), Day 1, Day 7 and Day 8.

  3. Amount of etrasimod excreted in breast milk

    Time frame: Baseline (Day -1), Day 1, Day 7 and Day 8.

  4. Percent of etrasimod dose excreted in breast milk

    Time frame: Baseline (Day -1), Day 1, Day 7 and Day 8.

  5. Breast milk clearance of etrasimod

    Baseline (Day -1), Day 1, Day 7 and Day 8.

    Time frame: Baseline through Day 8

  6. Time to maximum observed concentration of etrasimod

    Time frame: Baseline (Day -1), Day 1, Day 7 and Day 8.

Secondary outcomes

  1. Area under the etrasimod concentration-time curve in plasma

    Time frame: Day 1 hour 0, Day 7 hour 0, 1, 2, 4, 6, 8 and 12, Day 8 hour 24

  2. Maximum observed concentration of etrasimod in plasma

    Time frame: Day 1 hour 0, Day 7 hour 0, 1, 2, 4, 6, 8 and 12, Day 8 hour 24

  3. Time to maximum observed concentration of etrasimod in plasma

    Time frame: Day 1 hour 0, Day 7 hour 0, 1, 2, 4, 6, 8 and 12, Day 8 hour 24

  4. Breast milk to plasma ratio for area under the concentration-time curve

    Time frame: Baseline (Day -1), Day 1, Day 7 and Day 8.

  5. percentage of treatment emergent adverse events in participants

    Time frame: Baseline through Day 35

  6. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Time frame: Baseline through Day 8

  7. Number of Participants With Clinically Significant Change From Baseline in vital signs (blood pressure and heart rate)

    Time frame: Baseline through Day 8

  8. Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Parameters

    Time frame: Baseline through Day 8

  9. Body weight normalized infant dose in μg/kg/day

    Time frame: Baseline through Day 8

  10. Body weight normalized maternal dose in μg/kg/day

    Time frame: Baseline through Day 8

  11. Infant dose expressed as % of body weight normalized maternal dose

    Time frame: Baseline through Day 8

07

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région de B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Sep 2026, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Sep 3, 2025
StartActual
Aug 7, 2025
Primary completionActual
Sep 18, 2026
CompletionActual
Oct 15, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Oct 5, 2026 · changed Oct 20, 2026
Primary completion
Sep 12, 2026→Sep 18, 2026 (actual)
Oct 5, 2026
Study completion
Oct 12, 2026→Oct 15, 2026
Oct 5, 2026
Show all 2 updates
  1. Oct 20, 2026
    Active, not recruiting→Completed
    + 1 other change: date precision
  2. Oct 5, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 12, 2026→Sep 18, 2026 (now actual)
    Study completion Oct 12, 2026→Oct 15, 2026
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07153159
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Aug 7, 2025
Primary completion
Sep 18, 2026
Completion
Oct 15, 2026
Last update
Oct 20, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion